At a glance
- Originator Procter & Gamble
- Mechanism of Action Geranylgeranyltransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 19 Feb 2002 Preclinical development for Postmenopausal osteoporosis in USA (PO)